Serum Institute of India and Novavax together are set to produce 100 crore units of the COVID-19 vaccine.

Novavax and Serum Institute of India are in partnership to produce, commercialize, and develop up to one billion vaccine doses for India.

Serum Institute of India(SII), on August 07, 2020, stated that it had entered a new partnership with international vaccine alliance Gavi and Bill & Melinda Gates Foundation. The agreement is to speed up manufacturing and deliver up to one billion doses of COVID-19 vaccines for India and other low and middle-income countries(LMICs). It excludes significant upper-middle and high-income countries, for which Novavax continues to hold rights. The reports state that Novavax company expects the agreement to support a minimum of one billion doses of NVX-CoV2373 for India and low- and middle-income countries. SII has set an affordable ceiling price of US $3 per dose.